Formoterol in the management of chronic obstructive pulmonary disease

International Journal of COPD

Volumn 3, Issue 2, 2008, Pages 205-215

  Steiropoulos, Paschalis ^a   Tzouvelekis, Argyris ^a   Bouros, Demosthenes E ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Chronic obructive pulmonary disease; Formoterol; Long acting 2 agonists

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; IPRATROPIUM BROMIDE; LONG ACTING DRUG; METHYLXANTHINE; OXITROPIUM BROMIDE; OXYGEN; PLACEBO; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; STEROID; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ABDOMINAL PAIN; BACKACHE; BRONCHITIS; BRONCHODILATATION; BRONCHUS HYPERREACTIVITY; CANDIDIASIS; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DYSPEPSIA; DYSPHONIA; DYSPNEA; EXERCISE TOLERANCE; FEVER; GLUCOSE BLOOD LEVEL; HEART ARRHYTHMIA; HEART INFARCTION; HEART VENTRICLE SEPTUM RUPTURE; HUMAN; HYPERGLYCEMIA; HYPERINFLATION; HYPERTENSION; INFLAMMATION; INSOMNIA; LUNG FUNCTION; MONOTHERAPY; MUSCLE CRAMP; NAUSEA; NONHUMAN; PAIN; PHARMACODYNAMICS; PHARYNGITIS; PNEUMONIA; POTASSIUM BLOOD LEVEL; PRURITUS; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; REVIEW; RHINITIS; SIDE EFFECT; SINGLE DRUG DOSE; SYMPTOM; TACHYCARDIA; THORAX PAIN; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VOMITING; XEROSTOMIA;

ADRENERGIC BETA-AGONISTS; BRONCHOCONSTRICTION; DELAYED-ACTION PREPARATIONS; ETHANOLAMINES; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 47849122173     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Aalbers R, Ayres J, Backer V, et al. 2002. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J, 19:936-43.
2. Agusti AG. 2005. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc, 2:367-70; discussion 71-2.
3. Anderson R, Feldman C, Theron AJ, et al. 1996. Anti-inflammatory, membrane-stabilizing interactions of salmeterol with human neutrophils in vitro. Br J Pharmacol, 117:1387-94.
4. Bartow RA, Brogden RN. 1998. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs, 55:303-22.
5. Benhamou D, Cuvelier A, Muir JF, et al. 2001. Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). Respir Med, 95:817-21.
6. Bouros D, Kottakis J, Le Gros V, et al. 2004. Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility. Curr Med Res Opin, 20:581-6.
7. Bowden JJ, Sulakvelidze I, McDonald DM. 1994. Inhibition of neutrophil and eosinophil adhesion to venules of rat trachea by beta 2-adrenergic agonist formoterol. J Appl Physiol, 77:397-405.
8. Calverley PM, Anderson JA, Celli B, et al. 2007. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med, 356:775-89.
9. Calverley PM, Boonsawat W, Cseke Z, et al. 2003. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J, 22:912-9.
10. Calverley PM. 2001. Modern treatment of chronic obstructive pulmonary disease. Eur Respir J Suppl, 34:60s-6s.
11. Campbell M, Eliraz A, Johansson G, et al. 2005. Formoterol for maintenance and as needed treatment of chronic obstructive pulmonary disease. Respir Med, 99:1511-20.
12. Cazzola M, Di Marco F, Santus P, et al. 2004. The pharmacodynamic effects of single inhaled doses of formoterol"tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther, 17:35-39.
13. Cazzola M, Di Perna F, D'Amato M, et al. 2001. Formoterol Turbuhaler for as-needed therapy in patients with mild acute exacerbations of COPD. Respir Med, 95:917-21.
14. Cazzola M, Santangelo G, Piccolo A, et al. 1994. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol, 7:103-7.
15. Cazzola M, Santus P, Di Marco F, et al. 2003. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD. Respir Med, 97:453-7.
16. Cheer SM, Scott LJ. 2002. Formoterol: a review of its use in chronic obstructive pulmonary disease. Am J Respir Med, 1:285-300.
17. Coultas DB, Mapel D, Gagnon R, et al. 2001. The health impact of undiagnosed airflow obstruction in a national sample of United States adults. Am J Respir Crit Care Med, 164:372-7.
18. Dahl R, Greefhorst LA, Nowak D, et al. 2001. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 164:778-84.
19. Di Marco F, Verga M, Santus P, et al. 2006. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respir Med, 100:1925-32.
20. Di Marco F, Milic-Emili J, Boveri B, et al. 2003. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J, 21:86-94.
21. Donohue JF. 2004. Therapeutic responses in asthma and COPD. Bronchodilators. Chest, 126:125S-37S; discussion 59S-61S.
22. D'Urzo AD, De Salvo MC, Ramirez-Rivera A, et al. 2001. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3-week, randomized, double-blind, within-patient, multicenter study. Chest, 119:1347-56.
23. Faulds D, Hollingshead LM, Goa KL. 1991. Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs, 42:115-37.
24. Foradil. 2004. Formoterol dry-powder inhalation - Novartis/SkyePharma: Foradil MDDPI, Foradil MDPI, Foradil SkyeHaler, formoterol fumarate dry-powder inhalation. Drugs R D, 5:162-3.
25. Friedman M, Della Cioppa G, Kottakis J. 2002. Formoterol therapy for chronic obstructive pulmonary disease: a review of the literature. Pharmacotherapy, 22:1129-39.
26. Guhan AR, Cooper S, Oborne J, et al. 2000. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax. 55:650-6.
27. Guyatt GH, Berman LB, Townsend M, et al. 1987. A measure of quality of life for clinical trials in chronic lung disease. Thorax, 42:773-8.
28. Guyatt GH, Townsend M, Keller J, et al. 1989. Measuring functional status in chronic lung disease: conclusions from a randomized control trial. Respir Med, 83:293-7.
29. Johnson M, Rennard S. 2001. Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD. Chest, 120:258-70.
30. Jones PW, Quirk FH, Baveystock CM, et al. 1992. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis, 145:1321-7.
31. Kottakis J, Cioppa GD, Creemers J, et al. 2002. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. Can Respir J, 9:107-15.
32. Kottakis J, Wood R, Le Gros V, et al. 2001. Clinical efficacy with formoterol in the absence of a response to salmeterol: a review. Int J Clin Pract, 55:476-9.
33. Maesen BL, Westermann CJ, Duurkens VA, et al. 1999. Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease. Eur Respir J, 13:1103-8.
34. Mahler DA. 2002. The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease. J Allergy Clin Immunol, 110:S298-303.
35. Mahler DA, Tomlinson D, Olmstead EM, et al. 1995. Changes in dyspnea, health status, and lung function in chronic airway disease. Am J Respir Crit Care Med, 151:61-5.
36. Michaud CM, Murray CJ, Bloom BR. 2001. Burden of disease-implications for future research. JAMA, 285:535-9.
37. Murray CJ, Lopez AD. 1997. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet, 349:1498-504.
38. National Heart, Lung, and Blood Institute. 2006. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease.
39. Okada C, Sugiyama H, Eda R, et al. 1993. Effect of formoterol on superoxide anion generation from bronchoalveolar lavage cells after antigen challenge in guinea pigs. Am J Respir Cell Mol Biol, 8:509-17.
40. Oudijk EJ, Lammers JW, Koenderman L. 2003. Systemic inflammation in chronic obstructive pulmonary disease. Eur Respir J Suppl, 46:5s-13s.
41. Plant PK, Owen JL, Elliott MW. 2000. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Lancet, 355:1931-5.
42. Rabe KF, Giembycz MA, Dent G, et al. 1993. Salmeterol is a competitive antagonist at beta-adrenoceptors mediating inhibition of respiratory burst in guinea-pig eosinophils. Eur J Pharmacol, 231:305-8.
43. Redelmeier DA, Goldstein RS, Min ST, et al. 1996. Spirometry and dyspnea in patients with COPD. When small differences mean little. Chest, 109:1163-8.
44. Rossi A, Kristufek P, Levine BE, et al. 2002. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest, 121:1058-69.
45. Sears MR. 2002. Adverse effects of beta-agonists. J Allergy Clin Immunol, 110:S322-8.
46. Sichletidis L, Kottakis J, Marcou S, et al. 1999. Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD. Int J Clin Pract, 53:185-8.
47. Sin DD, McAlister FA, Man SF, et al. 2003. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA, 290:2301-12.
48. Sullivan SD, Ramsey SD, Lee TA. 2000. The economic burden of COPD. Chest, 117:5S-9S.
49. Szafranski W, Cukier A, Ramirez A, et al. 2003. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J, 21:74-81.
50. van Noord JA, Aumann JL, Janssens E, et al. 2005. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J, 26:214-22.
51. van Noord JA, Aumann JL, Janssens E, et al. 2006. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyper-inflation in patients with COPD. Chest, 129:509-17.
52. Verberne AA, Frost C, Roorda RJ, et al. 1997. One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group. Am J Respir Crit Care Med, 156:688-95.
53. Vervloet D, Ekstrom T, Pela R, et al. 1998. A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease. Respir Med, 92:836-42.
54. Ware JE Jr, Sherbourne CD. 1992. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care, 30:473-83.
55. Yan S, Kaminski D, Sliwinski P. 1997. Reliability of inspiratory capacity for estimating end-expiratory lung volume changes during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 156:55-9.